{"id":"irinotecan-liposome-5-fluorouracil-leucovorin","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Anemia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Mucositis"},{"rate":"10-20","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irinotecan is a camptothecin derivative that inhibits topoisomerase I, preventing DNA unwinding and causing cell death. The liposomal formulation improves drug delivery and reduces systemic toxicity. 5-Fluorouracil is an antimetabolite that inhibits thymidylate synthase and incorporates into DNA/RNA, while leucovorin (folinic acid) enhances 5-FU efficacy by stabilizing the FdUMP-thymidylate synthase complex.","oneSentence":"This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:51.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Pancreatic cancer (in development)"}]},"trialDetails":[{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":"Unresectable Pancreatic Cancer","enrollment":90},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT03483038","phase":"PHASE2","title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-12-13","conditions":"Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT07432568","phase":"PHASE2","title":"A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-09","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT03785873","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-05-22","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":224},{"nctId":"NCT06662006","phase":"PHASE2","title":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Advanced Metastatic Pancreatic Cancer","enrollment":56},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT07030283","phase":"PHASE1","title":"Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-31","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":10},{"nctId":"NCT07340151","phase":"NA","title":"Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT06821997","phase":"PHASE2","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-02-01","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT07314385","phase":"PHASE1","title":"NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Liver Metastasis","enrollment":24},{"nctId":"NCT04752696","phase":"PHASE2","title":"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2021-05-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT07183865","phase":"PHASE2","title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-09","conditions":"Locally Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT07173387","phase":"PHASE2","title":"Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-10-01","conditions":"Pancreatic Cancer","enrollment":42},{"nctId":"NCT07099794","phase":"PHASE2","title":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":90},{"nctId":"NCT07085273","phase":"PHASE2","title":"Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-08-15","conditions":"Gastric Cancer","enrollment":33},{"nctId":"NCT07074353","phase":"PHASE3","title":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-20","conditions":"Locally Advanced Rectal Cancer","enrollment":360},{"nctId":"NCT07060014","phase":"PHASE1","title":"NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-07-18","conditions":"Advanced Small Intestine Cancer, Appendiceal Cancers","enrollment":22},{"nctId":"NCT07047560","phase":"PHASE2","title":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer (CRC)","enrollment":46},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT03693677","phase":"PHASE2","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Metastatic Pancreatic Cancer","enrollment":288},{"nctId":"NCT03764553","phase":"PHASE2","title":"Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-05-01","conditions":"Esophageal Cancer","enrollment":320},{"nctId":"NCT04901741","phase":"PHASE2","title":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"TME Pharma AG","startDate":"2026-01","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06993025","phase":"PHASE2","title":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT04796948","phase":"PHASE1","title":"A Study of Irinotecan Liposome in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-08","conditions":"Advanced Pancreatic Cancer","enrollment":41},{"nctId":"NCT03861702","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:","status":"COMPLETED","sponsor":"Nelson Yee","startDate":"2020-09-02","conditions":"Locally Advanced Pancreatic Carcinoma(LAPC)","enrollment":28},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT05472259","phase":"PHASE2","title":"A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)","status":"RECRUITING","sponsor":"Belgian Group of Digestive Oncology","startDate":"2022-05-25","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":134},{"nctId":"NCT06736717","phase":"PHASE1, PHASE2","title":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-02","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT03736720","phase":"PHASE2","title":"Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-17","conditions":"Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma","enrollment":11},{"nctId":"NCT06643793","phase":"PHASE2","title":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-11-04","conditions":"Colorectal Neoplasms Malignant","enrollment":30},{"nctId":"NCT03719924","phase":"PHASE2","title":"Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2019-03-07","conditions":"Squamous Cell Carcinoma","enrollment":106},{"nctId":"NCT03837977","phase":"PHASE2","title":"Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2018-11-13","conditions":"Oncology, Neuroendocrine Carcinoma","enrollment":58},{"nctId":"NCT05859750","phase":"PHASE2","title":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-05-25","conditions":"Pancreatic Cancer","enrollment":78},{"nctId":"NCT06700603","phase":"PHASE2","title":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-11-20","conditions":"Pancreatic Cancer","enrollment":48},{"nctId":"NCT06688240","phase":"","title":"A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)","status":"NOT_YET_RECRUITING","sponsor":"Servier (Tianjin) Pharmaceutical Co. LTD.","startDate":"2024-11","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT06648525","phase":"PHASE2","title":"Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-10","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":68},{"nctId":"NCT06184698","phase":"PHASE2","title":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":173},{"nctId":"NCT06225999","phase":"PHASE2","title":"Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-04-25","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":41},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT06475326","phase":"PHASE2","title":"Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-05","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT02697058","phase":"PHASE2","title":"Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-03-30","conditions":"Metastatic Pancreatic Cancer","enrollment":84},{"nctId":"NCT03336216","phase":"PHASE2","title":"A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-18","conditions":"Advanced Pancreatic Cancer","enrollment":205},{"nctId":"NCT06501664","phase":"PHASE3","title":"Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-08-01","conditions":"Esophageal Cancer","enrollment":360},{"nctId":"NCT05009953","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma","enrollment":17},{"nctId":"NCT06387810","phase":"PHASE2","title":"Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-17","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":45},{"nctId":"NCT06467565","phase":"PHASE2","title":"NALIRIFOX as Induction Therapy in LAPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT03337087","phase":"PHASE1, PHASE2","title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2018-11-02","conditions":"Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma","enrollment":18},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT04371224","phase":"PHASE2","title":"NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-06-23","conditions":"Pancreatic Cancer","enrollment":200},{"nctId":"NCT06375642","phase":"PHASE2","title":"A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-10","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT06370754","phase":"PHASE1, PHASE2","title":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-04-30","conditions":"Pancreatic Cancer","enrollment":117},{"nctId":"NCT06345300","phase":"PHASE2","title":"NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-03-10","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":40},{"nctId":"NCT06259058","phase":"PHASE1, PHASE2","title":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-04-01","conditions":"Pancreatic Cancer","enrollment":96},{"nctId":"NCT06282120","phase":"","title":"Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-01-01","conditions":"Metastatic Biliary Tract Cancer","enrollment":30},{"nctId":"NCT06210360","phase":"PHASE2","title":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-02-01","conditions":"Pancreatic Cancer","enrollment":134},{"nctId":"NCT04617457","phase":"PHASE2","title":"Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas","status":"UNKNOWN","sponsor":"University of Cologne","startDate":"2021-10-10","conditions":"Pancreatic Cancer, Metastasis, Surgery","enrollment":150},{"nctId":"NCT06172036","phase":"PHASE2","title":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer","enrollment":180},{"nctId":"NCT05363007","phase":"PHASE2","title":"Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2022-05-01","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT05074589","phase":"PHASE3","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-01-25","conditions":"Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy","enrollment":298},{"nctId":"NCT05251038","phase":"PHASE1, PHASE2","title":"Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer","status":"WITHDRAWN","sponsor":"Devalingam Mahalingam","startDate":"2022-09-13","conditions":"Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03712397","phase":"PHASE2","title":"Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-12-24","conditions":"Head & Neck Cancer","enrollment":59},{"nctId":"NCT03665441","phase":"PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2018-09-15","conditions":"Pancreatic Adenocarcinoma","enrollment":512},{"nctId":"NCT02551991","phase":"PHASE2","title":"Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-10-19","conditions":"Pancreatic Cancer","enrollment":56},{"nctId":"NCT03883919","phase":"PHASE1","title":"Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-07-11","conditions":"Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas","enrollment":20},{"nctId":"NCT03487016","phase":"PHASE2","title":"First-line Therapy in Metastatic PDAC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-02-15","conditions":"Metastatic Pancreatic Cancer","enrollment":270},{"nctId":"NCT03524508","phase":"PHASE2","title":"Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"Changhoon Yoo","startDate":"2018-09-04","conditions":"Metastatic Biliary Tract Cancer","enrollment":178},{"nctId":"NCT03043547","phase":"PHASE2","title":"Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-10-24","conditions":"Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Cholangiocarcinoma of the Gallbladder","enrollment":100},{"nctId":"NCT04037241","phase":"PHASE2, PHASE3","title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-11-01","conditions":"Malignant Tumor of Pancreas Metastatic to Liver","enrollment":""},{"nctId":"NCT05095064","phase":"","title":"Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2021-09-27","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT05086848","phase":"PHASE1","title":"A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-05-05","conditions":"Advanced Solid Tumors","enrollment":15},{"nctId":"NCT03446872","phase":"","title":"Post Marketing Surveillance Study for ONIVYDE® in South Korea","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2018-03-08","conditions":"Metastatic Pancreatic Cancer","enrollment":94},{"nctId":"NCT05047991","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-10","conditions":"Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic","enrollment":153},{"nctId":"NCT03528785","phase":"PHASE2","title":"A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Centro Ricerche Cliniche di Verona","startDate":"2018-03-02","conditions":"Pancreatic Adenocarcinoma","enrollment":67},{"nctId":"NCT03703063","phase":"PHASE1","title":"Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Benaroya Research Institute","startDate":"2018-09-17","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT03986294","phase":"PHASE2","title":"Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-12-01","conditions":"Metastatic Pancreatic Cancer","enrollment":122},{"nctId":"NCT02785068","phase":"PHASE1, PHASE2","title":"Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Merrimack Pharmaceuticals","startDate":"2016-07","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT02884128","phase":"PHASE1","title":"A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors","status":"COMPLETED","sponsor":"PharmaEngine","startDate":"2006-01","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT01375816","phase":"PHASE2","title":"Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2011-05","conditions":"Colorectal Cancer","enrollment":55},{"nctId":"NCT00081536","phase":"PHASE1, PHASE2","title":"Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies","status":"UNKNOWN","sponsor":"Aronex Pharmaceuticals","startDate":"","conditions":"Colorectal Neoplasms","enrollment":105},{"nctId":"NCT00043199","phase":"PHASE2","title":"A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies","status":"UNKNOWN","sponsor":"Aronex Pharmaceuticals","startDate":"","conditions":"Colorectal Neoplasms","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Irinotecan liposome、5-Fluorouracil、Leucovorin","genericName":"Irinotecan liposome、5-Fluorouracil、Leucovorin","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells. Used for Metastatic colorectal cancer, Pancreatic cancer (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}